Alto Neuroscience Inc

ANRONYSE · USD
24.91USD-2.21 (-8.15%)
2510

Alto Neuroscience Inc (ANRO) Implied Volatility Current

ANRO's 30 day implied volatility is 90.30%, with an IV Rank of 19.44%. This is a low IV Rank versus the past year, meaning Alto Neuroscience Inc options are relatively cheap and currently favor buyers. ANRO's 30 day historical volatility sits at 82.30%, which means implied volatility is running 8.00 points above historical volatility, as of Nov 16, 2026.

Read more

Tracking ANRO implied volatility helps you spot when Alto Neuroscience Inc options are historically cheap or expensive, and where the best trades are hiding. When ANRO IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor ANRO implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking ANRO IV rank helps you see whether ANRO's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD.

Implied Volatility

IV Rank
19.44%IV Rank
Low

IV is subdued. Premiums are cheap, favoring buyers.

Implied Volatility (30d)90.30%

IV Rank19.44%

Historical Volatility (30d)82.30%

IV Minus HV+8.00%

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →